Logo
faq question Joey Med

Wegovy for Kids as Young as 6 in 2026: What the New STEP YOUNG Trial Means for Your Family

MD Telehealth Platform LLC DBA Joey Med is committed to protecting your health information in compliance with HIPAA regulations.
By Joey Med
5 min read
Published:
New NEJM trial: Wegovy cut BMI 13.5% in kids ages 6-11. What the STEP YOUNG results mean for parents, the side effects to know, and how adult GLP-1 treatment fits in.

New NEJM trial: Wegovy cut BMI 13.5% in kids ages 6-11. What the STEP YOUNG results mean for parents, the side effects to know, and how adult GLP-1 treatment fits in.

Overview

Weight loss medication news rarely makes the morning shows, but this week's did. On November 16, 2026, results from the STEP YOUNG trial were published in the New England Journal of Medicine and presented at ObesityWeek 2026: weekly semaglutide — the same medication sold as Wegovy — cut BMI by an average of 13.5% in children ages 6 to 11 with obesity, while children on placebo saw their BMI rise 2.7%. Wegovy is currently FDA-approved only for ages 12 and up, and Novo Nordisk has said it plans to ask the FDA to lower that age. For parents weighing what this means for their kids — and for adults managing their own weight at the same time — here's what the data actually shows, what doctors are cautioning, and how to think about it.

What the STEP YOUNG Trial Found

STEP YOUNG enrolled 167 children ages 6 to 11 with obesity — most with severe (class II or III) obesity — and randomized them 2:1 to weekly semaglutide or placebo for 68 weeks, alongside healthy-eating and activity counseling for everyone. The trial was funded by Novo Nordisk, Wegovy's manufacturer.

The headline numbers, as reported in the NEJM publication and news coverage:

  • BMI fell an average of 13.5% on semaglutide versus a 2.7% rise on placebo over 68 weeks.
  • About three in four children on semaglutide lowered their BMI by at least 10%.
  • 38.4% of children on semaglutide were no longer classified as having obesity by week 68, compared with just 2.1% on placebo.
  • Waist size, triglycerides, blood pressure, and a marker of inflammation all improved more on semaglutide than placebo.

Those are adult-sized results in a pediatric population — comparable in scale to what semaglutide produces in grown-ups. ABC News noted that nearly all of the children who received placebo still had obesity at the end of the trial, a reminder of how rarely severe childhood obesity resolves with lifestyle counseling alone.

The Side Effects Parents Should Know About

The tolerability picture is the part of this trial that deserves as much attention as the efficacy. Gastrointestinal side effects were very common: 70% of children on semaglutide experienced vomiting (versus 29% on placebo), 62% had diarrhea (versus 35%), and 58% had nausea (versus 24%).

Context matters here. Only about 4% of children stopped the medication because of side effects, serious adverse events were equally common in both groups (9% each), and investigators reported no effects on puberty or bone mineral density. The trial's authors described no new major safety concerns. But pediatricians quoted in the coverage were blunt that frequent vomiting lands differently in a 6-year-old than in an adult — it can mean missed school, disrupted routines, and real distress — and that longer follow-up on growth and body composition is still needed.

What Doctors and Guidelines Say

This is where the story gets genuinely contested. The American Academy of Pediatrics' 2023 guidelines recommend considering obesity medication for adolescents 12 and older. The World Health Organization went the other direction this fall, advising against obesity medications in children under 10. STEP YOUNG sits squarely in that disputed zone.

Specialists who reviewed the data called the results remarkable and said they could support a shift toward earlier treatment — particularly for children already dealing with weight-related complications like obstructive sleep apnea or high blood pressure. Others urged patience, noting that the drug is "a tool, not the only tool," and that key questions remain: which children benefit most, what happens after two years, and what long-term use through childhood development actually looks like.

For now, nothing changes at the pharmacy counter. Wegovy remains approved for ages 12 and up, prescribing below that age is off-label, and insurers rarely cover it for younger children. Any decision about medication for a child belongs with a pediatrician or pediatric obesity specialist who knows that child's health history.

Why This Matters for Adults, Too

If you're a parent reading this, there's a second takeaway hiding in the data: obesity runs in families, and the strongest predictor of a child's weight trajectory is the home environment — including the health of the adults in it.

The STEP YOUNG results underline something obesity specialists have argued for years: obesity is a chronic, biological disease that rarely resolves on its own, at any age. The placebo arm — children who received real lifestyle counseling for 68 weeks — actually gained BMI. Adults show the same pattern. Willpower alone is rarely a match for the biology of weight regulation, which is exactly why GLP-1 medications have become the standard of care for adults who qualify.

Parents who address their own weight often find it's the most practical first step for the whole household: the grocery list changes, portions change, activity changes — and unlike pediatric use, adult GLP-1 treatment is on-label, well studied, and widely accessible through telehealth.

How Adult GLP-1 Treatment Works at JoeyMed

JoeyMed treats adults 18 and over. If you've been thinking about your own weight while the headlines focus on kids, here's how to get started:

  1. Complete an online health assessment. A licensed provider reviews your history, BMI, medications, and goals to determine whether a GLP-1 is appropriate for you — including screening for contraindications like a personal or family history of medullary thyroid carcinoma or MEN 2, and pancreatitis history.
  2. Get a personalized plan. If you qualify, your provider can prescribe treatment such as compounded tirzepatide (Tirz HD), with dosing titrated gradually to limit the same GI side effects seen in every GLP-1 trial — nausea, vomiting, diarrhea, and constipation. Supportive options like anti-nausea medication can help during dose increases.
  3. Stay connected to your provider. Ongoing check-ins let you adjust dosing, manage side effects, and build the nutrition and strength-training habits that protect muscle while you lose fat.

GLP-1s aren't right for everyone, results vary, and treatment decisions should always be made with a licensed provider. But if this week's news has you thinking about your family's health, starting with your own is a decision you can act on today — visit JoeyMed Weight Loss to begin your consultation.

Wegovy for Kids as Young as 6 in 2026: What the New STEP YOUNG Trial Means for Your Family | Joey Med Blog – Joey Med | GLP-1 Telehealth Tampa FL